Xaluritamig by Amgen for Prostate Cancer: Likelihood of Approval

Xaluritamig is under clinical development by Amgen and currently in Phase I for Prostate Cancer.

CDC Tells Docs to Be on the Lookout for Bird Flu Cases

The CDC wants clinicians and health departments to consider potential infections with the highly pathogenic avian influenza (HPAI) A(H5N1) virus, commonly known as bird flu,

April 6, 2024

Lenvatinib mesylate by Eisai for Metastatic Biliary Tract Cancer: Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

December 24, 2023

Biophytis is deploying its partnership strategy in obesity – Biotech Investments

Biophytis / Key word(s): Miscellaneous Biophytis is deploying its partnership strategy in obesity 29-Apr-2024 / 14:39 CET/CEST Biophytis is deploying its partnership strategy in obesity

April 30, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.